biotech
biotech Articles
Many of the gout treatments on the market have been the same for decades, and many of them can come with their own sets of adverse side effects.
Published:
Last Updated:
The world of biotech can be a rags-to-riches story for companies that build up a drug candidate and secure FDA approval for that drug. And the larger the drug target group is, the more exciting it...
Published:
Last Updated:
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
Published:
Last Updated:
NewLink Genetics shares hit an all-time low in Monday’s session after the company provided an update on its brain tumor trial.
Published:
Last Updated:
Shares of Alkermes saw a handy gain to start out the week after the FDA made a critical decision about its treatment for major depressive disorder.
Published:
Last Updated:
Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study.
Published:
Last Updated:
These four top companies could be very attractive to large cap biotechs looking to add gene and cell therapy drugs to their portfolios.
Published:
Last Updated:
Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care has barely kept pace with the broader markets over the past 52 weeks, the...
Published:
Last Updated:
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Selecta Biosciences saw its shares sink on Tuesday after the company presented new data from patients receiving SEL-212 for the treatment of chronic severe gout.
Published:
Last Updated:
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a non-opioid...
Published:
Last Updated:
Surface Oncology intends to price 6 million shares to result in an initial public offering valued up to more than $103 million.
Published:
Last Updated:
Therapix Biosciences shares made a solid gain to start the week after it announced topline results for its cannabinoid product platform.
Published:
Last Updated:
Menlo Therapeutics shares were slaughtered early on Monday after the firm issued an update for its midstage clinical trial for patients with atopic dermatitis.
Published:
Last Updated:
Unity Biotechnology has filed with the SEC regarding its initial public offering.
Published:
Last Updated: